ArticleJournal of medical biochemistry2025
Serum levels of AFP and CA19-9 after intraoperative radiotherapy combined with drug therapy on liver and pancreatic tumors.
Article in Journal of medical biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To explore the efficacy of intraoperative radiotherapy combined with drug therapy on serum levels of AFP and CA19-9 for liver and pancreatic tumours to provide more effective treatment strategies for clinical practice. Methods: A retrospective analysis was conducted on 190 patients with liver and pancreatic tumours who underwent surgical resection combined with intraoperative radiotherapy in the hospital from March 2023 to September 2024. The patients were segmented into an experimental group (intraoperative radiotherapy combined with drug therapy, n = 95) and a control group (traditional treatment, n = 95) at random. After surgical resection, the experimental group accepted IORT targeted drugs, and immunomodulators. The control group received surgical resection and chemotherapy or external radiation therapy. The leading observation indicators include tumour marker levels, biochemical indicators, recurrence rate, survival rate, quality of life, postoperative complications, pain score, and psychological status. Results: The levels of AFP and CA19-9 in the experimental group decreased by 16.2 ng/mL and 74.7 U/mL, which surpassed those in the control group (P< 0.05). After treatment, the liver function indicators of the experimental group significantly improved (ALT decreased from 32 .1± 12.5 U/L to 22.4± 10.1 U/L, P = 0.00), and renal function also improved. The recurrence and metastasis rates in the experimental group were lower (P< 0.05). Although there was no discrepancy in common adverse reactions, the experimental group had a lower incidence of adverse reactions in radiation dermatitis and infection (P< 0.05). The survival curve demonstrated that the survival rate of the experimental group was higher (P< 0.05). Conclusions: Intraoperative radiotherapy combined with drug therapy has shown outstanding efficacy in treating liver and pancreatic tumours, effectively reducing tumour marker levels, improving liver and kidney function, reducing recurrence and metastasis rates, and improving survival rates and life quality while reducing postoperative complications and adverse reactions. This comprehensive treatment plan provides a new, effective strategy for treating liver and pancreatic tumours.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.